The anti-VEGF-A humanized IgG1 monoclonal antibody bevacizumab, which is an evidence-based option in numerous cancer types including, among others, metastatic colorectal cancer, has been the most extensively investigated anti-angiogenic drug in GEA. Here, VEGFA is linked to cancer.